ARIAD Pharma (ARIA) Director Whelan Resigns; Will CEO Berger be Next?
Get Alerts ARIA Hot Sheet
Join SI Premium – FREE
ARIAD Pharma (NASDAQ: ARIA) shares are up 2.3 percent Friday. After markets closed on Thursday, the company disclosed the following:
On September 13, 2014, Robert M. Whelan, Jr. notified ARIAD Pharmaceuticals, Inc. (the “Company”) that he will resign from the Company’s Board of Directors, effective October 1, 2014. Mr. Whelan has served as a director since April 2010 and currently serves as a member of the Audit Committee and the Compensation Committee. The Company, its leadership and its Board of Directors would like to thank Mr. Whelan for his many contributions to ARIAD, its shareholders and cancer patients.
Notably, infamous biotech blogger Adam Feuerstein sees an exit of CEO Harvey Berger happening sooner rather than later. You can see his latest blog post here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Starbucks (SBUX) announces executives for new global leadership positions
- Aspira Women’s Health (AWH) Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
- A.O. Smith (AOS) names Stephen Shafer as president and COO
Create E-mail Alert Related Categories
Insiders' Blog, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!